Martínez-García M A, Olveira C, Girón R, García-Clemente M, Máiz L, Sibila O, Golpe R, Rodríguez-Hermosa J L, Barreiro E, Méndez Raúl, Prados C, Rodríguez-López J, Oscullo G, de la Rosa D
Servicio de Neumología, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
CIBERES de Enfermedades Respiratorias. ISCIII. Madrid. Spain.
Pulmonology. 2025 Dec 31;31(1):2416836. doi: 10.1016/j.pulmoe.2023.11.006. Epub 2024 Oct 25.
The baseline value of eosinophils in peripheral blood (BEC) has been associated with different degrees of severity, prognosis and response to treatment in patients with bronchiectasis. It is not known, however, if this basal value remains constant over time.
The aim of this study was to assess whether the BEC remains stable in the long term in patients with bronchiectasis.
Patients from the RIBRON registry of bronchiectasis diagnosed by computed tomography with at least 2 BEC measurements one year apart were included in the study. Patients with asthma and those taking anti-eosinophilic drugs were excluded. Reliability was assessed using the intra-class correlation coefficient (ICC). A patient with a BEC of at least 300 cells/uL or less than 100 cells/uL was considered eosinophilic or eosinopenic, respectively. Group changes over time were also calculated.
Seven hundred and thirteen patients were finally included, with a mean age of 66.5 (13.2) years (65.8 % women). A total of 2701 BEC measurements were performed, with a median number of measurements per patient of 4 (IQR: 2-5) separated by a median of 12.1 (IQR: 10.5-14.3) months between two consecutive measurements. The ICC was good (>0.75) when calculated between two consecutive measurements (approximately one year apart) but had dropped significantly by the time of the next annual measurements. Similarly, the change from an eosinophilic or eosinopenic patient to a non-eosinophilic or non-eosinopenic patient, respectively, was less than 30 % during the first year with respect to the baseline value but was close to 50 % in later measurements.
Given the significant changes observed in the baseline value of the BEC over time, its monitoring is necessary in patients with bronchiectasis in order to more reliably assess its usefulness.
外周血嗜酸性粒细胞的基线值(BEC)与支气管扩张症患者的不同严重程度、预后及治疗反应相关。然而,尚不清楚该基线值是否随时间保持恒定。
本研究旨在评估支气管扩张症患者的BEC长期是否保持稳定。
本研究纳入了来自RIBRON支气管扩张症登记处、经计算机断层扫描诊断且两次BEC测量间隔至少一年的患者。排除哮喘患者及服用抗嗜酸性粒细胞药物的患者。使用组内相关系数(ICC)评估可靠性。BEC至少为300个细胞/微升或低于100个细胞/微升的患者分别被视为嗜酸性粒细胞增多或嗜酸性粒细胞减少。还计算了随时间的组间变化。
最终纳入713例患者,平均年龄66.5(13.2)岁(65.8%为女性)。共进行了2701次BEC测量,每位患者测量次数的中位数为4次(四分位间距:2 - 5次),两次连续测量的间隔中位数为12.1(四分位间距:10.5 - 14.3)个月。两次连续测量(间隔约一年)之间计算的ICC良好(>0.75),但到下一次年度测量时显著下降。同样,从嗜酸性粒细胞增多或嗜酸性粒细胞减少患者分别转变为非嗜酸性粒细胞增多或非嗜酸性粒细胞减少患者的比例,在第一年相对于基线值小于30%,但在后续测量中接近50%。
鉴于观察到BEC基线值随时间有显著变化,支气管扩张症患者有必要进行监测,以便更可靠地评估其效用。